The method, developed by researchers at Karolinska Institutet, could make a significant contribution to the development of new, improved drug substances.
Most drugs operate by binding to one or more proteins and affecting their function, which creates two common bottlenecks in the development of drugs; identifying the right target proteins and designing drug molecules able to efficiently seek out and bind to them.
No method has been available for directly measuring the efficiency of the drug molecules to locate and bind to its target protein.
"We have shown that the method works on a wide variety of target proteins and allows us to directly measure whether the drug molecules reach their targets in cells and animal models," said lead investigator Professor Par Nordlund of the Department of Medical Biochemistry and Biophysics.
"We believe that CETSA will eventually help to improve the efficiency of many drugs and contribute to better drug molecules and more successful treatments," Nordlund said.
The lack of methods to directly measure the binding of a drug to its target protein has caused a degree of uncertainty in many phases of drug development.
The group behind the study believes that CETSA will be an important control stage and a complement to other methods.
In the present study, the researchers also examined processes that can lead to drug resistance in cells.
The team believes that by virtue of its ability to determine whether existing drugs are suitable for individual patients, the method is of potential value to the practice of individualised treatment.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
